BONUSCAP-ZERTIFIKAT - EVOTEC Share Price

Certificat

DE000HC39ZW5

Real-time BOERSE MUENCHEN 08:46:37 17/06/2024 BST
8.08 EUR -3.35% Intraday chart for BONUSCAP-ZERTIFIKAT - EVOTEC
Current month-3.13%
1 month-18.28%
Date Price Change
17/06/24 8.08 -3.35%
14/06/24 8.36 -0.95%
13/06/24 8.44 -5.59%
12/06/24 8.94 +1.59%
11/06/24 8.8 +1.73%

Real-time BOERSE MUENCHEN

Last update June 17, 2024 at 08:46 am

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HC39ZW
ISINDE000HC39ZW5
Date issued 17/01/2023
Strike 22
Maturity 21/06/2024 (5 Days)
Parity 1 : 1
Emission price 16.78
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 20.8
Lowest since issue 8.08

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.4 EUR
Average target price
20.79 EUR
Spread / Average Target
+147.50%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW